ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Flamel Technologies SA Sponsored ADR (FLML) Report Updated: May 23, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Flamel Technologies SA Sponsored ADR (FLML)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Pharmaceuticals
Competitors: AMPE,PBH,SCLN,ADMP

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: D down no change
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

Flamel Technologies SA Sponsored ADR© quotemedia

Company Profile

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology primarily in the United States and Europe. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company’s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection; and Coreg CR, a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. In addition, it has various proprietary pipeline products, which are in various stages of development comprising Sodium Oxybate for patients suffering from narcolepsy; Ibuprofen for the treatment of pain; Guaifenesin for the treatment of chest congestion; and Exenatide for the treatment of type-2 diabetes. The company has collaborations with various pharmaceutical and biotechnology companies, including GlaxoSmithKline plc. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.